{"success":true,"data":{"pressRelease":{"id":"163244","rtpr_id":"nACSv1lZMa-20261007","ticker":"COSM","exchange":"NASDAQ","all_tickers":["COSM"],"title":"Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million","author":"ACCESSWIRE","published_at":"2026-10-07T13:34:54.521Z","article_body":"CHICAGO, IL / ACCESS Newswire (https://www.accessnewswire.com/) / October 7,\n2026 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company\") (NASDAQ:COSM\n(https://pr.report/s57u)), a diversified, vertically integrated global\nhealthcare group, today announced preliminary revenue of approximately $54.3\nmillion for the nine months ended September 30, 2026 - a Company record and an\nincrease of 19%, or $8.7 million, over the $45.6 million reported for the same\nperiod of 2025. Preliminary revenue for the third quarter was approximately\n$17.4 million, the highest third quarter in the Company's history. The Company\nalso reaffirmed its expectation that full-year 2026 revenue will surpass $90\nmillion.\n(https://app.accessnewswire.com/imagelibrary/9a13b004-c37a-4321-b437-993ea677d66d/1233926/cosmq3chart1kpisummary-002.png)\nNine Months That Nearly Equal a Full Year\n\nIn nine months, Cosmos Health has generated approximately the same revenue it\nreported for the whole of 2024, when full-year revenue was $54.4 million, and\n83% of the record $65.3 million reported for the whole of 2025. Measured\nagainst the first nine months of 2024, revenue is up 35%.\n(https://app.accessnewswire.com/imagelibrary/debe660e-e19d-4f19-bb15-d773dc0375f6/1233926/cosmq3chart2ninemonthrevenue.png)\nRecord Revenue in Every Quarter of 2026\n\nFirst, second and third-quarter revenue each exceeded the highest revenue the\nCompany had previously reported for that quarter. The third quarter was\nachieved against the most demanding comparison of the three.\n\nThird-quarter revenue of approximately $17.4 million compares with $17.1\nmillion in the third quarter of 2025 - which was, at the time, the highest\nquarterly revenue the Company had ever reported, and itself represented growth\nof 38%. Against that record base, third-quarter revenue increased again.\nMeasured over two years, third-quarter revenue is up 40% from $12.4 million in\nthe third quarter of 2024.\n\n REVENUE                      2024    2025    2026 (PRELIM.)       VS. 2025  VS. 2024  \n Third quarter                $12.4M  $17.1M  ~$17.4M              +2%       +40%      \n Nine months to September 30  $40.2M  $45.6M  ~$54.3M              +19%      +35%      \n Full year                    $54.4M  $65.3M  Over $90M (outlook)  +38%      +65%      \n\n2026 third-quarter and nine-month figures are preliminary and unaudited.\nFull-year 2026 reflects the Company's outlook, not results. Percentages are\ncalculated on rounded figures.\n\nGrowth Across the Company's Core Segments\n\nThe increase reflects growth across each of the Company's core segments.\nContract manufacturing at Cana Laboratories reached a record production\npipeline of more than 32.7 million units, and pharmaceutical distribution at\nCosmoFarm delivered record volumes across a network of more than 1,500\npharmacies that continues to expand. The Company's proprietary brands - among\nothers, Sky Premium Life, C-Scrub and C-Sept - grew in their established\nmarkets and entered new territories and channels globally, while sales\nmomentum in the United States continued to build.\n\n2026 Outlook Reaffirmed: Over $90 Million in Revenue\n\nCosmos Health reaffirms its previously announced expectation that revenue for\nfull-year 2026 will surpass $90 million, which would represent growth of\napproximately 38% over 2025. The Company currently expects the fourth quarter\nof 2026 to be the strongest quarter in its history, supported by contract\nmanufacturing orders, seasonal strength in distribution and accelerating sales\nin the United States.\n\nGreg Siokas, CEO of Cosmos Health, stated: \"In nine months we have delivered\napproximately what took us a full year in 2024. Revenue of approximately $54.3\nmillion is 19% ahead of last year, and it comes after a record first quarter,\na record second quarter and now a record third quarter - the third achieved\nagainst the most demanding comparison in the Company's history.\n\n\"That growth is coming from every part of the business. Our contract\nmanufacturing pipeline is at a record level, our distribution volumes are the\nhighest we have recorded, and our proprietary brands are growing in their\nestablished markets while reaching new ones.\n\n\"The infrastructure we have built over the past several years is now\nsupporting every part of the business, and we enter the final quarter with\nmomentum. We are reaffirming our outlook to surpass $90 million in revenue\nthis year, and we currently expect the fourth quarter to be the strongest in\nour history.\"\n\nPreliminary Results\n\nThe revenue figures in this release are preliminary and unaudited, are based\non information available to management as of the date of this release, and\nremain subject to the completion of the Company's quarter-end financial\nclosing procedures and review. Actual results may differ from these\npreliminary estimates. The Company's complete third-quarter results will be\nreported in its Quarterly Report on Form 10-Q for the period ended September\n30, 2026.\n\nAbout Cosmos Health Inc.\n\nCosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr,\nwww.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn\n(https://pr.report/s580) and X (https://pr.report/s581).\n\nForward-Looking Statements\n\nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas \"believes,\" \"expects,\" \"anticipates,\" \"intends,\" \"projects,\" \"estimates,\"\n\"plans,\" and similar expressions, or future or conditional verbs such as\n\"will,\" \"should,\" \"would,\" \"may,\" and \"could,\" generally identify\nforward-looking statements, although not all forward-looking statements\ncontain these words. These statements involve risks and uncertainties that may\nindividually or materially affect the matters discussed herein for a variety\nof reasons outside the Company's control, including, but not limited to: the\nCompany's ability to raise sufficient financing to implement its business\nplan; the effectiveness of its digital asset strategies, including\naccumulation and yield-generating activities; the impact of the war in Ukraine\nand ongoing conflicts in the Middle East and other regions on the Company's\nbusiness, operations, and the economy in general; the Company's ability to\nsuccessfully develop and commercialize its proprietary products and\ntechnologies; the timing, execution, regulatory clearance, valuation,\nstructuring, and completion of any potential asset-backed or tokenized\nfinancing program; the legal, regulatory, and technological risks associated\nwith digital assets and blockchain-based financial structures; the conversion\nof contract manufacturing pipeline volumes into production and revenue,\nincluding the timing, volume and terms of orders placed under multi-year\nagreements; the realization of anticipated gross margins; the timing, cost and\ncompletion of planned capital investments; changes in interest rates; changes\nin foreign currency exchange rates, commodity or other price inflation and\ndeflation; our ability to issue debt on terms and at rates acceptable to us;\nthe impact and expected outcome of investigations, inquiries, claims, and\nlitigation; the challenges of operating in international markets; the adequacy\nof insurance coverage; the effect of accounting charges and of adopting\ncertain accounting standards; the impact of legal and regulatory changes,\nincluding changes to tax laws and regulations; guidance for fiscal 2026 and\nbeyond and financial outlook. Forward-looking statements are based on\ncurrently available information and our current assumptions, expectations and\nprojections about future events. You should not rely on our forward-looking\nstatements. These statements are not guarantees of future performance and are\nsubject to future events, risks and uncertainties - many of which are beyond\nour control, dependent on the actions of third parties, or currently unknown\nto us - as well as potentially inaccurate assumptions that could cause actual\nresults to differ materially from our historical experience and our\nexpectations and projections. These risks and uncertainties include, but are\nnot limited to, those described from time to time in our periodic reports\nfiled with the SEC and available at the SEC's website (www.sec.gov). There\nalso may be other factors that we cannot anticipate or that are not described\nherein, generally because we do not currently perceive them to be material.\nSuch factors could cause results to differ materially from our expectations.\nForward-looking statements speak only as of the date they are made, and we do\nnot undertake to update these statements other than as required by law. You\nare advised, however, to review any further disclosures we make on related\nsubjects in our filings with the Securities and Exchange Commission and in our\nother public statements.\n\nInvestor Relations Contact:\n\nBDG Communications\ncosm@bdgcommunications.com\n\nSOURCE: Cosmos Health Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-reports-record-preliminary-nine-month-revenue-of-54.3-m-1233926)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSv1lZMa-20261007","title":"Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million","author":"ACCESSWIRE","ticker":"COSM","created":"2026-10-07T13:34:54.521Z","tickers":["COSM"],"exchange":"NASDAQ","article_body":"CHICAGO, IL / ACCESS Newswire (https://www.accessnewswire.com/) / October 7,\n2026 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company\") (NASDAQ:COSM\n(https://pr.report/s57u)), a diversified, vertically integrated global\nhealthcare group, today announced preliminary revenue of approximately $54.3\nmillion for the nine months ended September 30, 2026 - a Company record and an\nincrease of 19%, or $8.7 million, over the $45.6 million reported for the same\nperiod of 2025. Preliminary revenue for the third quarter was approximately\n$17.4 million, the highest third quarter in the Company's history. The Company\nalso reaffirmed its expectation that full-year 2026 revenue will surpass $90\nmillion.\n(https://app.accessnewswire.com/imagelibrary/9a13b004-c37a-4321-b437-993ea677d66d/1233926/cosmq3chart1kpisummary-002.png)\nNine Months That Nearly Equal a Full Year\n\nIn nine months, Cosmos Health has generated approximately the same revenue it\nreported for the whole of 2024, when full-year revenue was $54.4 million, and\n83% of the record $65.3 million reported for the whole of 2025. Measured\nagainst the first nine months of 2024, revenue is up 35%.\n(https://app.accessnewswire.com/imagelibrary/debe660e-e19d-4f19-bb15-d773dc0375f6/1233926/cosmq3chart2ninemonthrevenue.png)\nRecord Revenue in Every Quarter of 2026\n\nFirst, second and third-quarter revenue each exceeded the highest revenue the\nCompany had previously reported for that quarter. The third quarter was\nachieved against the most demanding comparison of the three.\n\nThird-quarter revenue of approximately $17.4 million compares with $17.1\nmillion in the third quarter of 2025 - which was, at the time, the highest\nquarterly revenue the Company had ever reported, and itself represented growth\nof 38%. Against that record base, third-quarter revenue increased again.\nMeasured over two years, third-quarter revenue is up 40% from $12.4 million in\nthe third quarter of 2024.\n\n REVENUE                      2024    2025    2026 (PRELIM.)       VS. 2025  VS. 2024  \n Third quarter                $12.4M  $17.1M  ~$17.4M              +2%       +40%      \n Nine months to September 30  $40.2M  $45.6M  ~$54.3M              +19%      +35%      \n Full year                    $54.4M  $65.3M  Over $90M (outlook)  +38%      +65%      \n\n2026 third-quarter and nine-month figures are preliminary and unaudited.\nFull-year 2026 reflects the Company's outlook, not results. Percentages are\ncalculated on rounded figures.\n\nGrowth Across the Company's Core Segments\n\nThe increase reflects growth across each of the Company's core segments.\nContract manufacturing at Cana Laboratories reached a record production\npipeline of more than 32.7 million units, and pharmaceutical distribution at\nCosmoFarm delivered record volumes across a network of more than 1,500\npharmacies that continues to expand. The Company's proprietary brands - among\nothers, Sky Premium Life, C-Scrub and C-Sept - grew in their established\nmarkets and entered new territories and channels globally, while sales\nmomentum in the United States continued to build.\n\n2026 Outlook Reaffirmed: Over $90 Million in Revenue\n\nCosmos Health reaffirms its previously announced expectation that revenue for\nfull-year 2026 will surpass $90 million, which would represent growth of\napproximately 38% over 2025. The Company currently expects the fourth quarter\nof 2026 to be the strongest quarter in its history, supported by contract\nmanufacturing orders, seasonal strength in distribution and accelerating sales\nin the United States.\n\nGreg Siokas, CEO of Cosmos Health, stated: \"In nine months we have delivered\napproximately what took us a full year in 2024. Revenue of approximately $54.3\nmillion is 19% ahead of last year, and it comes after a record first quarter,\na record second quarter and now a record third quarter - the third achieved\nagainst the most demanding comparison in the Company's history.\n\n\"That growth is coming from every part of the business. Our contract\nmanufacturing pipeline is at a record level, our distribution volumes are the\nhighest we have recorded, and our proprietary brands are growing in their\nestablished markets while reaching new ones.\n\n\"The infrastructure we have built over the past several years is now\nsupporting every part of the business, and we enter the final quarter with\nmomentum. We are reaffirming our outlook to surpass $90 million in revenue\nthis year, and we currently expect the fourth quarter to be the strongest in\nour history.\"\n\nPreliminary Results\n\nThe revenue figures in this release are preliminary and unaudited, are based\non information available to management as of the date of this release, and\nremain subject to the completion of the Company's quarter-end financial\nclosing procedures and review. Actual results may differ from these\npreliminary estimates. The Company's complete third-quarter results will be\nreported in its Quarterly Report on Form 10-Q for the period ended September\n30, 2026.\n\nAbout Cosmos Health Inc.\n\nCosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr,\nwww.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn\n(https://pr.report/s580) and X (https://pr.report/s581).\n\nForward-Looking Statements\n\nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas \"believes,\" \"expects,\" \"anticipates,\" \"intends,\" \"projects,\" \"estimates,\"\n\"plans,\" and similar expressions, or future or conditional verbs such as\n\"will,\" \"should,\" \"would,\" \"may,\" and \"could,\" generally identify\nforward-looking statements, although not all forward-looking statements\ncontain these words. These statements involve risks and uncertainties that may\nindividually or materially affect the matters discussed herein for a variety\nof reasons outside the Company's control, including, but not limited to: the\nCompany's ability to raise sufficient financing to implement its business\nplan; the effectiveness of its digital asset strategies, including\naccumulation and yield-generating activities; the impact of the war in Ukraine\nand ongoing conflicts in the Middle East and other regions on the Company's\nbusiness, operations, and the economy in general; the Company's ability to\nsuccessfully develop and commercialize its proprietary products and\ntechnologies; the timing, execution, regulatory clearance, valuation,\nstructuring, and completion of any potential asset-backed or tokenized\nfinancing program; the legal, regulatory, and technological risks associated\nwith digital assets and blockchain-based financial structures; the conversion\nof contract manufacturing pipeline volumes into production and revenue,\nincluding the timing, volume and terms of orders placed under multi-year\nagreements; the realization of anticipated gross margins; the timing, cost and\ncompletion of planned capital investments; changes in interest rates; changes\nin foreign currency exchange rates, commodity or other price inflation and\ndeflation; our ability to issue debt on terms and at rates acceptable to us;\nthe impact and expected outcome of investigations, inquiries, claims, and\nlitigation; the challenges of operating in international markets; the adequacy\nof insurance coverage; the effect of accounting charges and of adopting\ncertain accounting standards; the impact of legal and regulatory changes,\nincluding changes to tax laws and regulations; guidance for fiscal 2026 and\nbeyond and financial outlook. Forward-looking statements are based on\ncurrently available information and our current assumptions, expectations and\nprojections about future events. You should not rely on our forward-looking\nstatements. These statements are not guarantees of future performance and are\nsubject to future events, risks and uncertainties - many of which are beyond\nour control, dependent on the actions of third parties, or currently unknown\nto us - as well as potentially inaccurate assumptions that could cause actual\nresults to differ materially from our historical experience and our\nexpectations and projections. These risks and uncertainties include, but are\nnot limited to, those described from time to time in our periodic reports\nfiled with the SEC and available at the SEC's website (www.sec.gov). There\nalso may be other factors that we cannot anticipate or that are not described\nherein, generally because we do not currently perceive them to be material.\nSuch factors could cause results to differ materially from our expectations.\nForward-looking statements speak only as of the date they are made, and we do\nnot undertake to update these statements other than as required by law. You\nare advised, however, to review any further disclosures we make on related\nsubjects in our filings with the Securities and Exchange Commission and in our\nother public statements.\n\nInvestor Relations Contact:\n\nBDG Communications\ncosm@bdgcommunications.com\n\nSOURCE: Cosmos Health Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-reports-record-preliminary-nine-month-revenue-of-54.3-m-1233926)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-07T13:34:54.587083415Z","server_sent_at_ms":1791380094587},"received_at":"2026-10-07T13:34:54.637Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cosmos-health-reports-record-preliminary-nine-month-revenue-of-54.3-m-1233926"},"analysis":{"id":"151702","press_release_id":"163244","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Q3 revenue grew only ~2% YoY against the prior-year record, a sharp deceleration from prior 35-40% growth rates","figures are preliminary and unaudited, subject to quarter-end closing procedures","forward-looking statements reference digital asset strategies, tokenized financing programs, and pending investigations/litigation"],"eventType":"earnings","narrative":"Cosmos Health reported record preliminary nine-month 2026 revenue of approximately $54.3 million, up 19% year-over-year, with a record Q3 of approximately $17.4 million.\n\nThe company reaffirmed its full-year 2026 revenue outlook of more than $90 million, implying roughly 38% growth over 2025's $65.3 million, and expects Q4 to be its strongest quarter on record.\n\nAll figures are preliminary and unaudited; full Q3 results will come in the Form 10-Q. Growth was attributed to record contract manufacturing at Cana Laboratories, record distribution volumes at CosmoFarm, and expanding proprietary-brand sales.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Record nine-month revenue and reaffirmed $90M+ outlook -- but watch the ~2% Q3 YoY growth deceleration."},"keyFigures":{"revenue":54300000,"guidance":"Full-year 2026 revenue to surpass $90 million (reaffirmed), representing ~38% growth over 2025","revenueYoy":"19%","customDimensions":{"q3_revenue":17400000,"fy2024_revenue":54400000,"fy2025_revenue":65300000,"q3_revenue_yoy":"+2%","pharmacy_network":"more than 1,500 pharmacies","nine_month_2024_revenue":40200000,"nine_month_2025_revenue":45600000,"contract_manufacturing_pipeline_units":"more than 32.7 million units"}},"quotedText":"In nine months we have delivered approximately what took us a full year in 2024.","namedEntities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["Sky Premium Life","Mediterranation","bio-bebe","C-Sept","C-Scrub"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM","relationship":"filer"},{"name":"Cana Laboratories S.A.","relationship":"subsidiary"},{"name":"CosmoFarm","relationship":"subsidiary"},{"name":"ZipDoctor, Inc.","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"$54.3 million","context":"preliminary nine-month 2026 revenue"},{"amount":"$17.4 million","context":"preliminary Q3 2026 revenue"},{"amount":"$45.6 million","context":"nine-month 2025 revenue"},{"amount":"$90 million","context":"reaffirmed full-year 2026 revenue outlook"},{"amount":"$65.3 million","context":"full-year 2025 revenue"},{"amount":"$54.4 million","context":"full-year 2024 revenue"}]},"materialImpact":{"score":3,"reasoning":"Record preliminary nine-month revenue of $54.3M (+19% YoY) and reaffirmed FY2026 outlook above $90M (~38% growth), but figures are unaudited and Q3 growth was only ~2% YoY against a tough comp; no EPS or margin data provided."},"tickerRelevance":{"others":[],"primary":"COSM"},"globalImportance":28,"audienceRelevance":25,"eventTypeSecondary":["guidance_update"],"importanceComponents":{"note":"record growth headline offset by Q3 YoY growth of only ~2%","tickerTier":"small-cap","eventGravity":"preliminary revenue beat/records with guidance reaffirmation","householdBrandBoost":"low"}},"event_type":"earnings","event_type_secondary":["guidance_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Cosmos Health reported record preliminary nine-month 2026 revenue of approximately $54.3 million, up 19% year-over-year, with a record Q3 of approximately $17.4 million.\n\nThe company reaffirmed its full-year 2026 revenue outlook of more than $90 million, implying roughly 38% growth over 2025's $65.3 million, and expects Q4 to be its strongest quarter on record.\n\nAll figures are preliminary and unaudited; full Q3 results will come in the Form 10-Q. Growth was attributed to record contract manufacturing at Cana Laboratories, record distribution volumes at CosmoFarm, and expanding proprietary-brand sales.","key_figures":{"revenue":54300000,"guidance":"Full-year 2026 revenue to surpass $90 million (reaffirmed), representing ~38% growth over 2025","revenueYoy":"19%","customDimensions":{"q3_revenue":17400000,"fy2024_revenue":54400000,"fy2025_revenue":65300000,"q3_revenue_yoy":"+2%","pharmacy_network":"more than 1,500 pharmacies","nine_month_2024_revenue":40200000,"nine_month_2025_revenue":45600000,"contract_manufacturing_pipeline_units":"more than 32.7 million units"}},"named_entities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["Sky Premium Life","Mediterranation","bio-bebe","C-Sept","C-Scrub"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM","relationship":"filer"},{"name":"Cana Laboratories S.A.","relationship":"subsidiary"},{"name":"CosmoFarm","relationship":"subsidiary"},{"name":"ZipDoctor, Inc.","relationship":"subsidiary"}],"dollarAmounts":[{"amount":"$54.3 million","context":"preliminary nine-month 2026 revenue"},{"amount":"$17.4 million","context":"preliminary Q3 2026 revenue"},{"amount":"$45.6 million","context":"nine-month 2025 revenue"},{"amount":"$90 million","context":"reaffirmed full-year 2026 revenue outlook"},{"amount":"$65.3 million","context":"full-year 2025 revenue"},{"amount":"$54.4 million","context":"full-year 2024 revenue"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-07T13:35:02.597Z","global_importance":28,"audience_relevance":25,"importance_components":{"note":"record growth headline offset by Q3 YoY growth of only ~2%","tickerTier":"small-cap","eventGravity":"preliminary revenue beat/records with guidance reaffirmation","householdBrandBoost":"low"}},"durationMs":7946,"modelName":"glm-5.3-flashx"}}